Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Tue Apr 7, 5:38AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nektar Therapeutics (NKTR), Solventum Corporation (SOLV) and Immunovant (IMVT) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Nektar Therapeutics (NKTR)

In a report released today, Arthur He CFA from H.C. Wainwright reiterated a Buy rating on Nektar Therapeutics, with a price target of $135.00. The company’s shares closed last Thursday at $76.99.

According to TipRanks.com, CFA is a 5-star analyst with an average return of 41.8% and a 58.6% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Prime Medicine, Inc., and Satellos Bioscience. ;'>

Currently, the analyst consensus on Nektar Therapeutics is a Strong Buy with an average price target of $114.57, implying a 55.8% upside from current levels. In a report issued on March 30, William Blair also reiterated a Buy rating on the stock with a $68.00 price target.

See the top stocks recommended by analysts >>

Solventum Corporation (SOLV)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Solventum Corporation today and set a price target of $100.00. The company’s shares closed last Thursday at $63.57.

According to TipRanks.com, Zimmerman is a 1-star analyst with an average return of -0.4% and a 40.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Shoulder Innovations, Inc., and Tactile Systems Technology. ;'>

Currently, the analyst consensus on Solventum Corporation is a Moderate Buy with an average price target of $91.50, which is a 44.4% upside from current levels. In a report issued on March 22, TipRanks – PerPlexity also upgraded the stock to Buy with a $73.00 price target.

Immunovant (IMVT)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant today and set a price target of $42.00. The company’s shares closed last Thursday at $24.50.

According to TipRanks.com, Slutsky is a top 100 analyst with an average return of 40.2% and a 51.7% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ArriVent BioPharma, Inc., and Abivax SA Sponsored ADR. ;'>

Immunovant has an analyst consensus of Strong Buy, with a price target consensus of $39.73, which is a 67.2% upside from current levels. In a report issued on March 23, TipRanks – Google also upgraded the stock to Buy with a $26.00 price target.

Read More on NKTR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).